Personnel costs for human and generic drug review increased, while personnel costs for biosimilar review decreased, in FY 2019 compared to the previous year. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
